Cellmover
Pre-clinical immunotherapy company developing intracellular biologics to modulate T cell and NK cell function in the tumor microenvironment. The organization maintains a pipeline of three lead preclinical projects and conducts nanobody and peptide discovery, production and lead optimization from facilities based at incubators in Oslo.
Industries
Nr. of Employees
small (1-50)
Cellmover
ShareLab, Gaustadalléen 21, 0349 Oslo, Norway
Products
Three preclinical intracellular biologic drug candidates
A pipeline of three lead projects (intracellular biologic candidates) targeting intracellular proteins in immune cells, advanced through discovery, lead optimization and preclinical stages.
Three preclinical intracellular biologic drug candidates
A pipeline of three lead projects (intracellular biologic candidates) targeting intracellular proteins in immune cells, advanced through discovery, lead optimization and preclinical stages.
Services
Discovery, lead optimization and preclinical advancement of intracellular nanobody- and peptide-based biologic candidates intended to modulate immune cell function for cancer therapy.
Discovery, lead optimization and preclinical advancement of intracellular nanobody- and peptide-based biologic candidates intended to modulate immune cell function for cancer therapy.
Expertise Areas
- Preclinical drug development
- Nanobody and peptide therapeutics
- Intracellular biologics
- Protein expression and purification
Key Technologies
- Nanobody libraries
- Peptide therapeutics
- Intracellular biologic modalities
- Protein expression and purification
News & Updates
Appointment of Miriam Aarsund Larsen as CEO; former CEO remains as Chairman of the Board.
Company joined Aleap, an incubator for health and life science startups located at Oslo Science Park.
Company became a member of ShareLab to access laboratory facilities and collaborative resources.
Recognition awarded to the company's CSO as one of Norway's 50 leading women in tech 2025.
Press release published regarding company progress (December 2024).
Company CSO recognized among Norway's leading women in technology for 2025.
Appointment of Miriam Aarsund Larsen as CEO; former CEO remains as Chairman of the Board.
Company joined Aleap, an incubator for health and life science startups located at Oslo Science Park.
Company became a member of ShareLab to access laboratory facilities and collaborative resources.
Recognition awarded to the company's CSO as one of Norway's 50 leading women in tech 2025.
Press release published regarding company progress (December 2024).
Company CSO recognized among Norway's leading women in technology for 2025.